Clinical abuse potential study - MORPHABOND ER Vs MORPHABOND ER

Clinical abuse potential study—MORPHABOND ER: Crushed VS Intact

Whether MORPHABOND ER Was Taken Intact or Intranasally, There Was No Significant Preference for the Intranasal Route1,2

 

Mean Drug Liking

To assess Drug Liking, nondependent recreational opioid users in the study responded to the statement, “Do you like the drug effect you are feeling now?” by marking a single vertical line on a 100-mm bipolar visual analog scale (VAS). With abuse-deterrent formulations, the goal is to have subjects like the drug less.

 

Mean Take Drug Again

To assess Take Drug Again, nondependent recreational opioid users in the study responded to the statement, “Would you want to take the drug you just received again, if given the opportunity?” by marking a single vertical line on a 100-mm bipolar VAS. With abuse-deterrent formulations, the goal is for subjects to have less desire to take the drug again.

 
These data demonstrate that even if manipulated, MORPHABOND ER retains its extended-release properties
Abuse of MORPHABOND ER is still possible by intranasal, intravenous, and oral routes

Study design: The intranasal abuse potential and relative bioavailability of MORPHABOND ER was evaluated in a randomized, double-blind, double-dummy, placebo-controlled, single-dose, 4-way crossover study in 25 nondependent recreational opioid users comparing crushed intranasal MORPHABOND ER 60 mg, crushed intranasal MS Contin® 60 mg, and intact oral MORPHABOND ER 60 mg.

  • Primary endpoint: mean maximum effect (Emax) for drug liking between crushed intranasal MORPHABOND ER and crushed intranasal MS Contin®
  • Secondary comparisons for the primary endpoint included Emax for intact oral MORPHABOND ER compared with crushed intranasal MS Contin® and crushed intranasal MORPHABOND ER
  • Other secondary endpoints included Take Drug Again assessments and determining the relative bioavailability of morphine in plasma for crushed intranasal and intact oral MORPHABOND ER compared with crushed intranasal MS Contin®
  • Drug Liking (primary) and Take Drug Again (secondary) endpoints were measured on a 100-mm bipolar VAS where 50 represents a neutral response, 0 represents the strongest negative response, and 100 represents the strongest positive response

MORPHABOND ER VS MORPHABOND ER Navigation